Henry Schein, Inc.

LSE:0L3C Stock Report

Market Cap: US$8.7b

Henry Schein Valuation

Is 0L3C undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0L3C when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0L3C ($70.05) is trading above our estimate of fair value ($69.93)

Significantly Below Fair Value: 0L3C is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0L3C?

Key metric: As 0L3C is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0L3C. This is calculated by dividing 0L3C's market cap by their current earnings.
What is 0L3C's PE Ratio?
PE Ratio27.7x
EarningsUS$314.00m
Market CapUS$8.71b

Price to Earnings Ratio vs Peers

How does 0L3C's PE Ratio compare to its peers?

The above table shows the PE ratio for 0L3C vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.4x
MDC Mediclinic International
21.9x10.7%UK£3.7b
SN. Smith & Nephew
35x22.7%UK£8.5b
CTEC ConvaTec Group
37.1x20.2%UK£4.5b
SPI Spire Healthcare Group
31.8x26.9%UK£900.5m
0L3C Henry Schein
27.7x26.7%US$8.7b

Price-To-Earnings vs Peers: 0L3C is good value based on its Price-To-Earnings Ratio (27.7x) compared to the peer average (34.6x).

Price to Earnings Ratio vs Industry

How does 0L3C's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0L3C 27.7xIndustry Avg. 18.0xNo. of Companies8PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0L3C is expensive based on its Price-To-Earnings Ratio (27.7x) compared to the European Healthcare industry average (18x).

Price to Earnings Ratio vs Fair Ratio

What is 0L3C's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0L3C PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.7x
Fair PE Ratio44.9x

Price-To-Earnings vs Fair Ratio: 0L3C is good value based on its Price-To-Earnings Ratio (27.7x) compared to the estimated Fair Price-To-Earnings Ratio (44.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0L3C forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$70.05
US$74.83
+6.8%
9.7%US$83.00US$55.00n/a12
Dec ’25US$77.05
US$74.82
-2.9%
10.2%US$83.00US$55.00n/a11
Nov ’25US$70.69
US$74.73
+5.7%
10.2%US$83.00US$55.00n/a11
Oct ’25US$72.19
US$73.27
+1.5%
11.6%US$83.00US$55.00n/a11
Sep ’25US$71.02
US$74.18
+4.4%
13.2%US$92.00US$55.00n/a11
Aug ’25US$72.25
US$79.36
+9.8%
12.2%US$92.00US$60.00n/a11
Jul ’25US$65.09
US$79.08
+21.5%
9.6%US$92.00US$65.00n/a12
Jun ’25US$69.27
US$79.42
+14.7%
9.4%US$92.00US$65.00n/a12
May ’25US$69.22
US$80.63
+16.5%
7.8%US$90.00US$65.00n/a13
Apr ’25US$75.95
US$81.32
+7.1%
7.6%US$90.00US$65.00n/a13
Mar ’25US$77.13
US$79.92
+3.6%
7.8%US$90.00US$65.00n/a13
Feb ’25US$75.64
US$75.16
-0.6%
7.4%US$82.00US$65.00n/a12
Jan ’25US$75.27
US$73.99
-1.7%
7.3%US$82.00US$65.00n/a12
Dec ’24US$69.41
US$74.06
+6.7%
7.0%US$82.00US$65.00US$77.0512
Nov ’24US$63.60
US$79.81
+25.5%
7.1%US$90.00US$69.00US$70.6912
Oct ’24US$74.11
US$81.48
+9.9%
7.4%US$94.00US$69.00US$72.1912
Sep ’24US$76.06
US$82.84
+8.9%
8.4%US$96.00US$69.00US$71.0213
Aug ’24US$79.09
US$83.30
+5.3%
8.3%US$96.00US$69.00US$72.2513
Jul ’24US$81.26
US$83.07
+2.2%
8.5%US$96.00US$69.00US$65.0913
Jun ’24US$73.87
US$83.69
+13.3%
8.8%US$96.00US$69.00US$69.2713
May ’24US$81.31
US$84.23
+3.6%
8.9%US$97.00US$69.00US$69.2213
Apr ’24US$80.76
US$83.67
+3.6%
9.0%US$97.00US$69.00US$75.9512
Mar ’24US$77.27
US$83.58
+8.2%
9.5%US$97.00US$69.00US$77.1312
Feb ’24US$86.51
US$82.67
-4.4%
9.3%US$99.00US$70.00US$75.6412
Jan ’24US$79.81
US$81.50
+2.1%
10.0%US$99.00US$70.00US$75.2712
Dec ’23US$82.59
US$81.67
-1.1%
9.7%US$99.00US$71.00US$69.4112

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 19:35
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/28
Annual Earnings2023/12/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Henry Schein, Inc. is covered by 38 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey JohnsonBaird
Ishan MajumdarBaptista Research
Lawrence MarshBarclays